RxDoctor Payments Data

Brandon Kai, MD

Interventional Cardiology · Honolulu, HINPI 1285913632

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (46.2%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Edwards Lifesciences at 37.3% of the total.

$3,164in general payments, 2019–2025

Across 48 payments — averaging $65.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$1K
  • Medtronic$461
  • Boehringer Ingelheim$362
  • W. L. Gore & Associates, Inc.$315
  • AstraZeneca$249
  • Vapotherm Inc$124
  • plus $472 from 9 others

What the payments were for

  • Consulting fees$44014%
  • Speaking & faculty fees$31510%
  • Travel & lodging$94730%
  • Food & beverage$1,46346%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional cardiology providers in Hawaiito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$217,782
Medicare patients
2,132
Services billed
5,036

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban961$967,309
EntrestoSacubitril/Valsartan199$227,489
FarxigaDapagliflozin Propanediol101$95,925
JardianceEmpagliflozin94$94,683
XareltoRivaroxaban67$74,686
Repatha SureclickEvolocumab61$34,690
BrilintaTicagrelor24$20,153
Atorvastatin Calcium341$11,398
Repatha PushtronexEvolocumab16$9,837
Metoprolol Succinate582$9,443
VascepaIcosapent Ethyl16$8,097
ClopidogrelClopidogrel Bisulfate134$4,122
Amiodarone Hcl76$3,014
Rosuvastatin Calcium74$2,777
Ezetimibe36$2,031

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$24$967,309961 claims
AstraZenecaFarxiga, Brilinta$249$116,079125 claims
Boehringer IngelheimJardiance$362$94,68394 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional cardiology providers in Hawaiion file to place this against a meaningful peer group, so we don't.

Other interventional cardiology in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →